Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Karen M. Mann Ph.D.

Karen M. Mann, Ph.D.

Karen M. Mann, Ph.D.

Karen M. Mann, Ph.D.

 

Senior Research Associate
Cancer Research Program
The Methodist Hospital Research Institute

E-mail: kmmann@houstonmethodist.org
Phone: 713-441-1161


Education

B.A.   Boston University, Boston MA (Biochemistry and Molecular Biology)
Ph.D.   Case Western Reserve University, Cleveland OH (Genetics)
     

Postdoctoral Training

Research Fellow, Division of Genetics and Genomics, Institute for Molecular and Cell Biology, Singapore

Postdoctoral Fellow, Cancer Genetics Program, National Cancer Institute, Frederick, MD 

 

Biography

Dr. Mann earned her Ph.D. in Genetics from Case Western Reserve University in 2005. She then joined the laboratory of Drs. Neal Copeland and Nancy Jenkins at the National Cancer Institute in Frederick, MD where she initiated a forward-genetic screen in mice to identify genes involved in pancreatic cancer development.  In 2006, she followed Drs. Copeland and Jenkins to Singapore, where she developed several mouse models of cancer, including pancreas, liver, lung and leukemia, using Sleeping Beauty insertional mutagenesis. Dr. Mann joined The Methodist Hospital Research Institute in 2011. As a member of the TMHRI Cancer Research Program, Dr. Mann directs a research program focusing on the identification of genes involved in the initiation, progression and metastasis of epithelial tumors, with a particular interest in pancreatic ductal adenocarcinoma. She is an associate member of the American Association for Cancer Research. 

Description of Research

Dr. Mann’s research program focuses on defining the genes that cooperate with known oncogenes in human pancreatic cancer to drive tumor initiation, progression and metastasis.  She is characterizing the relatedness of individual primary tumors and their metastases using high throughput sequencing and gene expression platforms.  She is also developing a platform to identify resistance loci for cancer therapies.

Major Areas of Research

Cancer, pancreas, metastasis, drug resistance, genetic screens

Recent Publications

Biankin AV, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012 Nov 15;491(7424):399-405. PMID: 23103869

Mann KM, Ward JM, Yew CC, Kovochich A, Dawson DW, Black MA, Brett BT, Sheetz TE, Dupuy AJ; Australian Pancreatic Cancer Genome Initiative, Chang DK, Biankin AV, Waddell N, Kassahn KS, Grimmond SM, Rust AG, Adams DJ, Jenkins NA, Copeland NG. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):5934-41. PMID: 22421440

Goh AM, Lim CY, Chiam PC, Li L, Mann MB, Mann KM, Menendez S, Lane DP. Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity. Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1685-90. PMID: 22307631